Integra Announces Completion of Refinancing Transactions
The refinancing combines notes due 2033 with revolving and term loan facilities carrying five and seven year maturities.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Integra LifeSciences Holdings (NASDAQ: IART) completed a refinancing that included a private offering of $450.0 million in senior secured notes. The notes carry a 9.500% interest rate and mature in 2033.
The amended and restated credit facility totals approximately $1.65 billion: a $600 million revolving facility and a $600 million term loan A, each with a five year maturity, plus a $450 million term loan B with a seven year maturity. All three facilities are senior secured. Net note proceeds and credit facility borrowings refinanced the existing credit facility and paid transaction fees and expenses. The notes are guaranteed by wholly-owned domestic subsidiaries that guarantee the credit facility.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Major pointRefinancing of the existing credit facility is completed.
- Major pointPrivate note offering raised $450.0 million in aggregate principal financing. 44% of market cap
- Minor pointRevolving credit facility provides $600 million with a five year maturity.
Negative
- Major pointSenior secured notes impose 9.500% interest on $450.0 million principal due 2033. 44% of market cap
- Minor pointSenior secured term loan A facility totals $600 million with a five year maturity.
- Minor pointSenior secured term loan B facility totals $450 million with a seven year maturity.
- Minor pointRefinancing proceeds also covered transaction fees and expenses.
Key Figures
- Senior secured notes principal
- $450.0 million
- Private offering; closed
- Notes interest rate
- 9.500%
- Senior secured notes due 2033
- Notes maturity
- 2033
- Senior secured notes
- Revolving credit facility
- $600 million
- Senior secured
- Term loan A
- $600 million
- Senior secured; five-year maturity
- Term loan A maturity
- Five years
- Senior secured term loan A
- Term loan B
- $450 million
- Senior secured; seven-year maturity
- Term loan B maturity
- Seven years
- Senior secured term loan B
Historical Context
-
Priced the same $450 million 9.500% notes due 2033, with closing expected Oct. 19.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
senior secured notes financial
revolving credit facility financial
rule 144a regulatory
regulation s regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it has closed a private offering of
Integra used the net proceeds, together with borrowings under the Credit Facility, to refinance its existing credit facility and pay fees and expenses in connection with the foregoing.
The Notes and the related guarantees have not been, and will not be, registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state or other jurisdiction. The Notes were offered only to persons reasonably believed to be qualified institutional buyers in reliance on the exemption from registration provided by Rule 144A of the Securities Act and to certain non-U.S. persons outside of the United States in compliance with Regulation S of the Securities Act.
This press release is being issued pursuant to Rule 135c of the Securities Act and is neither an offer to sell, nor a solicitation of an offer to buy, any of the securities mentioned above and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. Any offer of the securities mentioned above will be made only by means of a private offering memorandum.
About Integra
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect Integra’s judgment as of the date of this release. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like “will,” “believe,” “may,” “could,” “would,” “might,” “possible,” “should,” “expect,” “intend,” “plan,” “anticipate,” or “continue,” the negative of these words, other terms of similar meaning or they may use future dates. Forward-looking statements contained in this press release include, but are not limited to, the expectations, plans and prospects for Integra, including the anticipated use of proceeds of the offering of the Notes and borrowings under the Credit Facility, which should be the many risks and uncertainties that affect Integra’s business and market, including market and other general economic conditions, and other risks identified under the heading “Risk Factors” included in item 1A of Integra’s Annual Report on Form 10-K for the year ended December 31, 2025, and information contained in subsequent filings with the Securities and Exchange Commission. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. These forward-looking statements are made only as of the date hereof, and Integra undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Investor Relations Contacts:
Chris Ward
(609) 772-7736
chris.ward@integralife.com
Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the terms of Integra's new refinancing notes?
Integra closed a private offering of $450.0 million in 9.500% senior secured notes due 2033. The notes are guaranteed by the wholly-owned domestic subsidiaries that also guarantee its credit facility.
What facilities make up Integra's amended credit agreement?
The approximately $1.65 billion credit facility comprises a $600 million revolving facility, a $600 million term loan A facility and a $450 million term loan B facility. The revolver and term loan A each have a five year maturity; term loan B has a seven year maturity. All are senior secured.